OBI Pharma, Inc. is an innovative biotechnology company. Our mission is to improve the quality of life of patients through the development of novel therapeutic agents that address unmet medical needs by targeting the Globo series antigens Globo H and SSEA-4, and the AKR1C3 enzyme that are all over-expressed in multiple tumor types. OBI Pharma''s pipeline includes a First-in-Class vaccine (Phase III), mAbs, and ADCs (Phase I/II) targeting Globo H and SSEA-4 and a First-in-Class small molecule prodrug (Phase I/II) that targets cancers that over-express the Aldo Keto Reductase 1C3 enzyme (AKR1C3).